Market Place
Sourcing Support
GigaGen Doses 1st Patient in Ph 1 of GIGA-2339 for Hepatitis B
19 Nov 2024 //
GLOBENEWSWIRE
GigaGen garners up to $135M BARDA bucks to beat botulism
03 Oct 2024 //
FIERCE BIOTECH
GigaGen Doses First GIGA-564 Anti-CTLA-4 Solid Tumor Patient
20 May 2024 //
GLOBENEWSWIRE
GigaGen Receives FDA Clearance of IND to Begin Phase 1 Trial of GIGA-564
12 Dec 2023 //
GLOBENEWSWIRE
GigaGen Granted Expansion of Contract to Develop Synthetic Human Antibody
19 Oct 2023 //
GLOBENEWSWIRE
GigaGen Partners with the National Cancer Institute to Advance Oncology Drug
28 Sep 2023 //
GLOBENEWSWIRE
GigaGen’s use of 2G UNicTM tech extended by ProteoNic
01 Nov 2022 //
PHARMATIMES
GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic
15 Sep 2022 //
GLOBENEWSWIRE
GigaGen Publishes Research on Clinical GMP Manufacturing & IND-Enabling Studies
28 Jul 2022 //
GLOBENEWSWIRE
GigaGen Publishes Research on the Potential of its Machine Learning Platform
19 May 2022 //
GLOBENEWSWIRE
GigaGen Publishes Research update on GIGA-564
14 Jul 2021 //
GLOBENEWSWIRE
GigaGen Publishes Research on Company’s Recombinant Hyperimmunes
15 Apr 2021 //
GLOBENEWSWIRE
GigaGen Initiates Large-Scale Manufacturing of Hyperimmune Drug for COVID-19
09 Sep 2020 //
GLOBENEWSWIRE
GigaGen works on recombinant polyclonal antibody against Covid-19
31 Mar 2020 //
PHARMACEUTICAL TECHNOLOGY
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.